Categories: News

TRACON to Report Fourth Quarter and Full Year 2020 Financial Results and Company Highlights on February 25, 2021

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its fourth quarter and full year 2020 financial and operating results after the close of U.S. financial markets on Thursday, February 25, 2021. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

Conference call and webcast:
Date: February 25, 2021
Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)
Dial-in: (855) 779-9066 (Domestic) or (631) 485-4859 (International)
Passcode: 5681569
Via web: www.traconpharma.com; “Events and Presentations” section within the “Investors” section

A replay of the webcast will be available for 60 days on the website.

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization.  In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S.  To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.

Company Contact: Investor Contact:
Mark Wiggins Brian Ritchie
Chief Business Officer LifeSci Advisors LLC
(858) 251-3492 212-915-2578
mwiggins@traconpharma.com  

Staff

Recent Posts

Innovaccer Expands its HXP Capabilities with the Launch of AI-Powered Healthcare Contact Center

The contact center solution is ushering in a new era of healthcare, by driving next-level…

3 seconds ago

Prevencio Selected for Prestigious MedTech Innovator 2024 Accelerator Cohort

KIRKLAND, Wash.--(BUSINESS WIRE)--Prevencio, Inc., a leader in AI-powered blood tests for cardiovascular diagnostics, has been…

2 mins ago

Veterinary Practice Management Software Market to be Worth $674.5 Million by 2031- Exclusive Report by Meticulous Research®

REDDING, Calif., June 5, 2024 /PRNewswire/ -- According to a new market research report titled, "Veterinary Practice…

7 mins ago

Ambulatory EHR Market to be Worth $7.84 billion by 2031 – Exclusive Report by Meticulous Research®

REDDING, Calif., June 5, 2024 /PRNewswire/ -- According to a new market research report, "Ambulatory EHR…

7 mins ago

Enspectra Health Receives FDA Breakthrough Device Designation for AI-powered Imaging Platform Targeting Skin Cancer

MOUNTAIN VIEW, Calif., June 5, 2024 /PRNewswire/ -- Enspectra Health, a health tech company, today…

7 mins ago

AvaSure Teams Up with CLEW Medical to Boost High-Acuity Care with AI-Driven Virtual Surveillance

The open AvaSure Virtual Care ecosystem enables the CLEW AI-powered, FDA-cleared predictive analytics solution for accurate…

8 mins ago